JAMA Oncology

Medications

Pembrolizumab use supported in advanced melanoma

(HealthDay)—Use of pembrolizumab is supported among patients with advanced melanoma, regardless of BRAF V600E/K mutation status or prior receipt of a BRAF inhibitor (BRAFi) with or without MEK inhibitor (MEKi) therapy, ...

page 23 from 40